Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Department of Radiation Oncology, Haaglanden MC, The Hague, The Netherlands.
Acta Oncol. 2020 Jul;59(7):809-817. doi: 10.1080/0284186X.2020.1750693. Epub 2020 Apr 14.
: Stereotactic body radiation therapy (SBRT) results in high local control (LC) rates in patients with non-small cell lung cancer (NSCLC). For central lung tumors, risk-adapted fractionation schedules are used and underdosage to the Planned Target Volume (PTV) is often accepted to respect the dose constraints of the organs at risk in order to avoid high rates of toxicity. The purpose of this study was to analyze the effect of PTV underdosage and other possible prognostic factors on local- and disease control after SBRT in patients with central lung tumors.: Patients with centrally located NSCLC treated with SBRT were included. The doses were converted into biologically equivalent dose using α/β-value of 10 Gy (BED). Underdosage to the PTV was defined as the (percentage of) PTV receiving less than 100 Gy BED; (%)PTV < 100 BED. Potential prognostic factors for LC and Disease Free Survival (DFS) were evaluated using Cox regression analysis.: Two hundred and twenty patients received ≤12 fractions of SBRT. LC-rates were 88% at 2 years and 81% at 3 years. Twenty-seven patients developed a local recurrence. Both the PTV < 100 BED and %PTV < 100 BED were not prognostic for LC. Tumor size and forced expiratory volume in 1 second (FEV) were independently prognostic for LC. Disease progression was reported in 75 patients with DFS-rates of 66% at 2 years and 56% at 3 years. Disease recurrence was independent significantly associated with larger tumor diameter, lower lobe tumor location and decreased FEV. Grade 4-5 toxicity was reported in 10 patients (8 with ultra-central tumors) and was fatal in at least 3 patients.: Decrease in tumor coverage was not correlated with the local recurrence probability. The LC and DFS were promising after SBRT of centrally located NSCLC with tumor size, FEV and tumor location (for DFS only) as prognostic factors.
立体定向体部放射治疗(SBRT)可使非小细胞肺癌(NSCLC)患者获得较高的局部控制率(LC)。对于中央型肺部肿瘤,采用风险适应分割方案,通常会接受对计划靶区(PTV)的剂量不足,以保护危及器官的剂量限制,从而避免高毒性发生率。本研究旨在分析PTV 剂量不足和其他可能的预后因素对中央型肺部肿瘤 SBRT 后局部和疾病控制的影响。
纳入接受 SBRT 治疗的中央型 NSCLC 患者。将剂量转换为等效生物剂量(BED),采用α/β值为 10 Gy。PTV 剂量不足定义为 PTV 接受的剂量低于 100 Gy BED 的(百分比);(%)PTV < 100 BED。采用 Cox 回归分析评估 LC 和无病生存(DFS)的潜在预后因素。
220 例患者接受≤12 次 SBRT 治疗。2 年和 3 年时 LC 率分别为 88%和 81%。27 例患者出现局部复发。PTV < 100 BED 和%PTV < 100 BED 均与 LC 无关。肿瘤大小和 1 秒用力呼气量(FEV)是 LC 的独立预后因素。75 例患者发生疾病进展,2 年和 3 年时 DFS 率分别为 66%和 56%。疾病复发与肿瘤直径较大、下叶肿瘤位置和 FEV 降低显著相关。10 例患者(8 例为超中央肿瘤)出现 4-5 级毒性,至少有 3 例患者死亡。
肿瘤覆盖率的降低与局部复发概率无关。对于中央型 NSCLC,SBRT 后肿瘤大小、FEV 和肿瘤位置(DFS 仅)作为预后因素,LC 和 DFS 均有较好的结果。